Plural 1,3-diazine Rings Patents (Class 544/296)
-
Publication number: 20120157427Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.Type: ApplicationFiled: November 9, 2011Publication date: June 21, 2012Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
-
Publication number: 20120157431Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.Type: ApplicationFiled: December 23, 2011Publication date: June 21, 2012Inventors: David Ranulf Cheshire, Rhona Jane Cox, Premji Meghani, Neal Michael Smith, Jeffrey Paul Stonehouse, Cherylin Francis Preston
-
Publication number: 20120157412Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
-
Patent number: 8202868Abstract: The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, R1 and R1a are as defined in the claims.Type: GrantFiled: August 8, 2005Date of Patent: June 19, 2012Assignee: Abbott GmbH & Co. KGInventors: Andreas Haupt, Liliane Unger, Karla Drescher, Ana Lucia Jongen-Relo, Roland Grandel, Wilfried Braje, Herve Geneste
-
Patent number: 8202863Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).Type: GrantFiled: April 4, 2008Date of Patent: June 19, 2012Assignee: Aventis Pharmaceuticals Inc.Inventors: Suzanne C. Aldous, John Ziqi Jiang, Jinqi Lu, Liang Ma, Lan Mu, Harry Randall Munson, Jeffrey Stephen Sabol, Sukanthini Thurairatnam, Christopher Loren Vandeusen
-
Publication number: 20120149904Abstract: The present invention relates to compounds of formula a process for their production and their use in electronic devices, especially electroluminescent devices. When used as electron transport material in electroluminescent devices, the compounds of formula I, or II may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Applicant: BASF SEInventors: Thomas Schäfer, Heinz Wolleb, Christian Schildknecht, Soichi Watanabe, Christian Lennartz
-
Publication number: 20120149723Abstract: This invention relates to heteroaryloxy 5-methyl substituted piperidine derivatives and their use as pharmaceuticals.Type: ApplicationFiled: August 16, 2010Publication date: June 14, 2012Inventor: Romano Di Fabio
-
Publication number: 20120149711Abstract: This invention relates to heteroarylamine methyl substituted piperidine derivatives (I) and their use as antagonists of human orexin.Type: ApplicationFiled: August 16, 2010Publication date: June 14, 2012Inventor: Romano Di Fabio
-
Patent number: 8197722Abstract: Compositions capable of simultaneous two-photon absorption and higher order absorptivities are provided. Compounds having a donor-pi-donor or acceptor-pi-acceptor structure are of particular interest, where the donor is an electron donating group, acceptor is an electron accepting group, and pi is a pi bridge linking the donor and/or acceptor groups. The pi bridge may additionally be substituted with electron donating or withdrawing groups to alter the absorptive wavelength of the structure. Also disclosed are methods of generating an excited state of such compounds through optical stimulation with light using simultaneous absorption of photons of energies individually insufficient to achieve an excited state of the compound, but capable of doing so upon simultaneous absorption of two or more such photons. Applications employing such methods are also provided, including controlled polymerization achieved through focusing of the light source(s) used.Type: GrantFiled: July 30, 2001Date of Patent: June 12, 2012Assignee: The California Institute of TechnologyInventors: Seth Marder, Joseph Perry
-
Publication number: 20120142717Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.Type: ApplicationFiled: December 5, 2011Publication date: June 7, 2012Inventors: Yun JIN, Zehong WAN, Qing ZHANG
-
Publication number: 20120142716Abstract: The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.Type: ApplicationFiled: August 15, 2008Publication date: June 7, 2012Inventors: Martin Bolli, Christoph Boss, Alexander Treiber
-
Publication number: 20120142706Abstract: Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.Type: ApplicationFiled: August 3, 2010Publication date: June 7, 2012Inventors: Harold B. Wood, Alan D. Adams, Jason W. Szewczyk, Yong Zhang, Meng Yang
-
Publication number: 20120138912Abstract: A biscarbazole derivative of the invention is represented by a formula (1) below. In the formula (1): A1 represents a substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; A2 represents a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 ring carbon atoms, or substituted or unsubstituted nitrogen-containing heterocyclic group having 1 to 30 ring carbon atoms; X1 and X2 each are a linking group; Y1 to Y4 each represent a substituent; p and q represent an integer of 1 to 4; and r and s represent an integer of 1 to 3.Type: ApplicationFiled: February 14, 2012Publication date: June 7, 2012Inventors: Tetsuya Inoue, Mitsunori Ito, Kei Yoshida, Kumiko Hibino, Kazuki Nishimura, Toshinari Ogiwara, Kiyoshi Ikeda
-
Publication number: 20120136015Abstract: The present invention relates to processes for the preparation of an endothelial receptor antagonist. The present invention particularly relates to synthesis of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzene sulfonamide (bosentan).Type: ApplicationFiled: April 9, 2010Publication date: May 31, 2012Applicant: SANDOZ AGInventors: Shreerang Joshi, Rashid Khan, Deven Bendre, Dadasaheb Salunkhe, Sanket Gudekar
-
Patent number: 8188087Abstract: The present invention relates to novel crystalline forms of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate and to pharmaceutical compositions containing said forms.Type: GrantFiled: April 24, 2007Date of Patent: May 29, 2012Assignee: Merck Patent GmbHInventors: Susan Marie Reutzel-Eden, Gregory Alan Stephenson
-
Publication number: 20120126221Abstract: A charge-transporting material contains a compound represented by the following formula (1) in an organic layer, in which the contents of specific halogen-containing compounds are 0.1% or less to the compound represented by formula (1). In formula (1), each of A1 and A2 independently represents N, —CH or —CR; R represents a substituent; L represents a single bond, an arylene group, a cycloalkylene group or an aromatic heterocyclic group; each of R1 to R5 independently represents a substituent; each of n1, n2 and n3 independently represents an integer of 0 to 4; each of n4 and n5 independently represents an integer of 0 to 5; and each of p and q independently represents an integer of 1 to 4.Type: ApplicationFiled: July 27, 2010Publication date: May 24, 2012Applicant: FUJIFILM CORPORATIONInventors: Tetsu Kitamura, Toru Watanabe, Toshihiro Ise, Hiroo Takizawa
-
Publication number: 20120129856Abstract: The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.Type: ApplicationFiled: October 18, 2011Publication date: May 24, 2012Applicant: Cerenis Therapeutics SAInventors: Daniela Carmen Oniciu, Jean-Louis Henri Dasseux, Ronald Barbaras, Valery Kochubey, Dmitry Kovalsky, Oleg Gennadievich Rodin, Otto Geoffroy, Anna Rzepiela
-
Publication number: 20120130073Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.Type: ApplicationFiled: October 7, 2011Publication date: May 24, 2012Applicant: Portola Pharmaceuticals, Inc.Inventors: Zhaozhong Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
-
Publication number: 20120122906Abstract: Disclosed is a novel compound which has both angiotensin II receptor antagonist activity and PPAR? activating activity, and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, kidney diseases, arteriosclerosis, inflammatory diseases, type 2 diabetes, diabetic complication, insulin resistant syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. Also disclosed is a pharmaceutical composition which contains the novel compound. Specifically disclosed are: a sulfonamide derivative represented by general formula (I), a salt thereof, or a solvate of the derivative or salt; and a pharmaceutical composition which contains the sulfonamide derivative, a salt thereof, or a solvate of the derivative or salt.Type: ApplicationFiled: August 27, 2010Publication date: May 17, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Noriaki Gomi, Takaaki Araki, Junya Tagashira, Ryohei Sekimoto, Rio Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120107271Abstract: The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.Type: ApplicationFiled: August 19, 2009Publication date: May 3, 2012Inventors: Cecil D. Kwong, F. George Njoroge, Subramaniam Ananthan, Ashok Arasappan, Frank Bennett, Jeremy Clark, Anita T. Fowler, Feng Geng, Hollis S. Kezar, III, Joseph A. Maddry, John J. Piwinski, Robert C. Reynolds, Abhijit Roychowdhury, John A. Secrist, III, Neng-Yang Shih
-
Publication number: 20120104941Abstract: A compound for an organic photoelectric device, an organic photoelectric device, and a display device, the compound being represented by the following Chemical Formula 3a, 3b, or 3c:Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Inventors: Sung-Hyun JUNG, Myeong-Soon KANG, Ho-Kuk JUNG, Nam-Soo KIM, Dong-Min KANG, Nam-Heon LEE, Mi-Young CHAE
-
Publication number: 20120097899Abstract: The present invention describes novel indenofluorene derivatives which can preferably be employed as matrix materials for phosphorescent dopants or as electron-transport materials, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to polymers which comprise these compounds as structural units and to a process for the preparation of the compounds according to the invention and to electronic devices which comprise same.Type: ApplicationFiled: June 1, 2010Publication date: April 26, 2012Inventors: Amir Hossain Parham, Christof Pflumm, Teresa Mujica-Fernaud, Arne Buesing, Holger Heil
-
Publication number: 20120076756Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 4, 2011Publication date: March 29, 2012Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Publication number: 20120076835Abstract: This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.Type: ApplicationFiled: September 30, 2011Publication date: March 29, 2012Inventors: Jérôme Emile Georges Guillemont, Patrice Palandijian, Marc René De Jonge, Lucien Maria Henricus Koymans, Hendrik Maarten Vinkers, Frederik Frans Desiré Daeyaert, Jan Heeres, Koen Jeanne Alfons Van Aken, Paulus Joannes Lewi, Paul Adriaan Jan Janssen, Frank Xavier Jozef Herwig Arts
-
Publication number: 20120071480Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: ApplicationFiled: December 1, 2011Publication date: March 22, 2012Inventors: Xiaomei Feng, Huiping Guan, Stephanos Ioannidis, Bo Peng, Mei Su, Tao Wang, Hai-Jun Zhang, Ying Kan, Bin Wang
-
Publication number: 20120068170Abstract: The present invention describes indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices or as matrix material. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.Type: ApplicationFiled: May 3, 2010Publication date: March 22, 2012Applicant: MERCK PATENT GmbHInventors: Christof Pflumm, Arne Buesing, Amir Hossain Parham, Teresa Mujica-Fernaud, Holger Heil, Philipp Stoessel
-
Publication number: 20120059014Abstract: The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicant: PROSIDION LIMITEDInventors: Oscar Barba, Tom Banksia Dupree, Peter Timothy Fry, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Karen Lesley Schofield, Donald Smyth, Thomas Staroske, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain, David Matthew Withall
-
Publication number: 20120053175Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.Type: ApplicationFiled: November 25, 2009Publication date: March 1, 2012Applicant: UNIVERSITY OF ROCHESTERInventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
-
Publication number: 20120041200Abstract: The invention concerns a new process for the preparation of bosentan or bosentan monohydrate by reaction of compound of Formula II with ethylene glycol in the presence of potassium bases and the potassium salt of bosentan.Type: ApplicationFiled: March 3, 2010Publication date: February 16, 2012Inventors: Giancarlo Biffi, Lazzaro Feliciani, Enrico Viscardi
-
Publication number: 20120040991Abstract: Disclosed are 3-azabicyclo[4.1.0]heptane derivatives of formula (I) and their use as orexin receptor antagonists.Type: ApplicationFiled: April 23, 2010Publication date: February 16, 2012Applicant: Glaxo Group LimitedInventors: David Amantini, Romano Di Fabio, Massimo Gianotti, Francesca Pavone, Francesco Ferroni
-
Publication number: 20120028962Abstract: A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: —COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.Type: ApplicationFiled: February 17, 2010Publication date: February 2, 2012Inventors: Kentaro Rikimaru, Hiroshi Imoto, Masahiro Kamaura
-
Publication number: 20120029002Abstract: The present application relates to novel fused, heteroatom-bridged pyrazole and imidazole derivatives, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: January 5, 2010Publication date: February 2, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Alexander Straub, Frank Süßmeier, Frank Wunder, Johannes-Peter Stasch, Volkhart Min-Jian Li, Joachim Mittendorf
-
Publication number: 20120028983Abstract: Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPAR? activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.Type: ApplicationFiled: April 16, 2010Publication date: February 2, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Seiichi Sato, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Publication number: 20120028997Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: ApplicationFiled: December 16, 2010Publication date: February 2, 2012Inventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara Miskowski, Janet L. Ralbovsky, Mark Schulz
-
Patent number: 8106045Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R? represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).Type: GrantFiled: September 9, 2005Date of Patent: January 31, 2012Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi-AventisInventors: Kazutoshi Watanabe, Fumiaki Uehara, Shinsuke Hiki, Toshiyuki Kohara, Kenji Fukunaga, Satoshi Yokoshima
-
Patent number: 8093246Abstract: O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described.Type: GrantFiled: December 12, 2007Date of Patent: January 10, 2012Assignee: Lexicon Pharmaceuticals, Inc.Inventors: David J. Augeri, Marianne Carlsen, Kenneth G. Carson, Qinghong Fu, Jason P. Healy, Alexander Heim-Riether, Theodore C. Jessop, Philip E. Keyes, Min Shen, James E. Tarver, Jerry A. Taylor, Xiaolian Xu
-
Patent number: 8093245Abstract: 4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed.Type: GrantFiled: December 12, 2007Date of Patent: January 10, 2012Assignee: Lexicon Pharmaceuticals, Inc.Inventors: David J. Augeri, Marianne Carlsen, Kenneth G. Carson, Qinghong Fu, Alexander Heim-Riether, Theodore C. Jessop, James E. Tarver, Jerry A. Taylor
-
Patent number: 8093385Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.Type: GrantFiled: July 28, 2008Date of Patent: January 10, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Romyr Dominique, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri
-
MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME
Publication number: 20120001165Abstract: Provided is an organic electroluminescent device (organic EL device), which has improved luminous efficiency, has sufficient driving stability, and has a simple construction. The organic EL device of the present invention is an organic electroluminescent device, including a light-emitting layer and a hole-transporting layer between an anode and a cathode laminated on a substrate, in which the light-emitting layer contains a phosphorescent light-emitting dopant and an indolocarbazole compound that serves as a host material, or alternatively, the hole-transporting layer contains an indolocarbazole compound. The indolocarbazole compound is represented by the following formula (1). In the formula: A1's each represent an aromatic hydrocarbon group or an aromatic heterocyclic group, provided that at least one of A1's has a fused ring structure; and R1's each represent a hydrogen atom, an alkyl group, an alkoxy group, or an acyl group.Type: ApplicationFiled: March 25, 2010Publication date: January 5, 2012Inventors: Masaki Komori, Takahiro Kai, Toshihiro Yamamoto -
Patent number: 8088784Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: GrantFiled: February 26, 2010Date of Patent: January 3, 2012Assignee: AstraZeneca ABInventors: Xiaomei Feng, Huiping Guan, Ying Kang, Stephanos Ioannidis, Bo Peng, Mei Su, Bin Wang, Tao Wang, Hai-Jun Zhang
-
Publication number: 20110318280Abstract: Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethylenimine polymers, for example, substitution with aralkyl groups, are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as cosmetics, hair care products and textiles, as well as in applications with much less human contact, such as coatings.Type: ApplicationFiled: September 7, 2011Publication date: December 29, 2011Inventors: Xinyu Huang, Ted Deisenroth, Andrea Preuss, Sophie Marquais-Bienewald, Carmen Hendricks-Guy, John Jennings
-
Publication number: 20110319614Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:Type: ApplicationFiled: September 8, 2011Publication date: December 29, 2011Applicant: NOVARTIS AGInventors: Zhuoliang CHEN, Run-Ming David WANG, Ming CHEN, Christopher Sean STRAUB, Leigh ZAWEL
-
Publication number: 20110319420Abstract: The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR.Type: ApplicationFiled: December 24, 2009Publication date: December 29, 2011Applicant: HARBIN GLORIA PHARMACEUTICALS CO., LTDInventors: Xuqing Yang, Long Xue, Juan Luo
-
Publication number: 20110312996Abstract: The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: May 16, 2011Publication date: December 22, 2011Applicant: InterMune, Inc.Inventors: Brad Buckman, John B. Nicholas, Vladimir Serebryany, Scott D. Seiwert
-
Patent number: 8080551Abstract: HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.Type: GrantFiled: June 26, 2006Date of Patent: December 20, 2011Assignee: Janssen Pharmaceutica N.V.Inventors: Jérôme Emile Georges Guillemont, Patrice Palandijian, Marc René De Jonge, Lucien Maria Henricus Koymans, Hendrik Maarten Vinkers, Frederik Frans Desiré Daeyaert, Jan Heeres, Koen Jeanne Alfons Van Aken, Paulus Joannes Lewi, Paul Adriaan Jan Janssen, Frank Xavier Jozef Herwig Arts, legal representative
-
Publication number: 20110306623Abstract: Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease, angina, cerebral vascular accident, cerebrovascular disorder, ischemic peripheral circulatory disorder, kidney disease, atherosclerosis, inflammatory disease, type 2 diabetes mellitus, diabetic complication, insulin resistance syndrome, Syndrome X, metabolic syndrome, and hyperinsulinemia.Type: ApplicationFiled: February 22, 2010Publication date: December 15, 2011Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Junya Tagashira, Gen Watanabe, Ryohei Sekimoto, Rie Ishida, Tadaaki Ohgiya
-
Publication number: 20110306589Abstract: The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, R1, R2, R3, R4, R5 and R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.Type: ApplicationFiled: June 2, 2011Publication date: December 15, 2011Inventors: Konrad Bleicher, Alexander Flohr, Katrin Groebke Zbinden, Felix Gruber, Matthias Koerner, Bernd Kuhn, Jens-Uwe Peters, Rosa Maria Rodriguez Sarmiento
-
Publication number: 20110301123Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein R1, R2, R9a, R9b, G, W, X, Y, and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: August 16, 2011Publication date: December 8, 2011Applicant: E.I. DU PONT NEMOURS AND COMPANYInventor: Paula Louise Sharpe
-
Publication number: 20110301109Abstract: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.Type: ApplicationFiled: December 10, 2009Publication date: December 8, 2011Applicants: TOPHARMAN SHANGHAI CO., LTD.Inventors: Zheng Liu, Jianfeng Li, Xiaojun Yang, Zhen Wang, Jinfeng Zhang, Yi Zhu, Guanghui Tian, Qing Jin, Jingkang Shen, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
-
Publication number: 20110294836Abstract: Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.Type: ApplicationFiled: June 16, 2009Publication date: December 1, 2011Applicant: METABOLEX, INC.Inventors: Jiangao Song, Jingyuan Ma, Christopher J. Rabbat, Imad Nashashibi, Xin Chen, Zuchun Zhao